Literature DB >> 2214791

Renal vein leiomyosarcoma.

J J Pelton1, J P Palazzo, R O Peterson, B L Eisenberg.   

Abstract

The 11th case of primary leiomyosarcoma of the renal vein is reported. Unique features of this case included concomitant resection of an isolated hepatic metastasis, intraoperative radiation therapy, and the use of electron microscopy and immunohistochemical stains in confirming the diagnosis. A review of the previously reported cases shows a tendency toward slow tumor growth and infrequent recurrence (18%). Metastases are common (82%), primarily to the lung and liver. Aggressive surgical resection and adjuvant radiation therapy, including intraoperative radiation therapy, are recommended. Adjuvant chemotherapy should be considered, although its benefits at present are unclear.

Entities:  

Mesh:

Year:  1990        PMID: 2214791     DOI: 10.1002/jso.2930450214

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  4 in total

Review 1.  Venous invasion in renal vein leiomyosarcoma: case report and review of the literature.

Authors:  M Lipton; S Sprayregen; R Kutcher; A Frost
Journal:  Abdom Imaging       Date:  1995 Jan-Feb

2.  Leiomyosarcoma of the renal vein: analysis of outcome and prognostic factors in the world case series of 67 patients.

Authors:  Marko Novak; Andraz Perhavec; Katherine E Maturen; Snezana Pavlovic Djokic; Simona Jereb; Darja Erzen
Journal:  Radiol Oncol       Date:  2016-12-23       Impact factor: 2.991

3.  Clinical experience with the treatment of retroperitoneal vascular leiomyosarcoma originating from large veins.

Authors:  Hong-Xian Zhang; Kai Wang; Peng Hong; Min Lu; Zhuo Liu; Lei Liu; Guo-Liang Wang; Lu-Lin Ma
Journal:  BMC Surg       Date:  2021-08-15       Impact factor: 2.102

4.  Clinical experience and treatment strategy of leiomyosarcoma originating from the renal vein.

Authors:  Qais Baheen; Hai Bi; Kai Wang; Min Lu; Hongxian Zhang; Lulin Ma
Journal:  Eur J Med Res       Date:  2022-06-27       Impact factor: 4.981

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.